Biotech · Private company
Orbus Therapeutics, Inc.
Track this companyFree. Adds Orbus Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- EflornithinePhase 3 · Anaplastic AstrocytomaClinicalTrials.gov · fetched Nov 12, 2026
- LomustinePhase 3 · Anaplastic AstrocytomaClinicalTrials.gov · fetched Nov 12, 2026
- Eflornithine (Dose Level 1)Phase 1 · Glioblastoma, IDH-wildtypeClinicalTrials.gov · fetched Nov 12, 2026
- Eflornithine (Dose Level 2)Phase 1 · Glioblastoma, IDH-wildtypeClinicalTrials.gov · fetched Nov 12, 2026
- TemozolomidePhase 1 · Glioblastoma, IDH-wildtypeClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or AstrocytomaPHASE1 · RECRUITING · started Jul 24, 2023ClinicalTrials.gov NCT05879367 · fetched Nov 12, 2026
- Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) PatientsPHASE3 · UNKNOWN · started Jul 1, 2016ClinicalTrials.gov NCT02796261 · fetched Nov 12, 2026